Nature Reviews Clinical Oncology (@natrevclinonc.nature.com)

The changing landscape of oncology clinical trials in Latin America Nature Reviews Clinical Oncology, Published online: 04 March 2026; doi:10.1038/s41571-026-01137-yAlthough oncology advances stem from clinical research,

04.03.2026 17:19 👍 0 🔁 0 💬 0 📌 0

Lisocabtagene maraleucel has high efficacy in R/R MZL Nature Reviews Clinical Oncology, Published online: 03 March 2026; doi:10.1038/s41571-026-01138-xLisocabtagene maraleucel has high efficacy in R/R MZL

03.03.2026 12:54 👍 0 🔁 0 💬 0 📌 0

Perioperative approaches for patients with biliary tract cancer Nature Reviews Clinical Oncology, Published online: 03 March 2026; doi:10.1038/s41571-026-01130-5Cholangiocarcinomas, comprising intrahepatic, extrahepatic and perihilar subtypes as well as gallbladder cancer, are a heterogeneous group of malignancies that necessitates a personalized approach to both surgery and systemic therapy. In this Review, the authors describe progress in the development of personalized perioperative therapy strategies as well as the most promising future research directions in this diverse and often difficult-to-treat group of cancers.

03.03.2026 12:54 👍 2 🔁 0 💬 0 📌 0

Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer Nature Reviews Clinical Oncology, Published online: 02 March 2026; doi:10.1038/s41571-026-01139-wEnfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer

02.03.2026 15:31 👍 0 🔁 1 💬 0 📌 0

Translating ferroptosis into oncology: challenges, opportunities and future directions Nature Reviews Clinical Oncology, Published online: 24 February 2026; doi:10.1038/s41571-026-01128-zDespite substantial interest in exploiting ferroptosis — an iron-mediated, lipid peroxidation-driven form of cell death — for cancer therapy, progress towards clinical translation has been limited. This comprehensive Review describes the major barriers that have restricted ferroptosis-based therapeutic development as well as emerging opportunities presented by new ferroptosis-inducing agents, biomarker-guided patient selection and rational combination treatments.

25.02.2026 09:36 👍 1 🔁 0 💬 0 📌 0

Innovative approaches for lung cancer screening and interception Nature Reviews Clinical Oncology, Published online: 23 February 2026; doi:10.1038/s41571-026-01131-4Effective early detection and intervention strategies for lung cancer are urgently needed. The authors of this Review summarize the current state of lung cancer screening and provide future directions for optimal implementation, including biomarker development. They also discuss precancer interception strategies that could transform both lung cancer prevention and early intervention.

23.02.2026 15:09 👍 0 🔁 0 💬 0 📌 0

Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling Nature Reviews Clinical Oncology, Published online: 20 February 2026; doi:10.1038/s41571-026-01126-1Analysis of tumour tissue to guide the clinical management of patients with cancer poses several challenges. This Review outlines the potential of liquid biopsy-based analysis of circulating tumour DNA (ctDNA) to address these limitations and thereby improve precision medicine in the context of metastatic colorectal cancer, as well as opportunities to refine the management of locoregional disease using recurrence risk-tailored approaches predicated on ctDNA-based evaluation of minimal residual disease status.

20.02.2026 21:39 👍 2 🔁 0 💬 0 📌 0

Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours Nature Reviews Clinical Oncology, Published online: 18 February 2026; doi:10.1038/s41571-026-01136-zRepotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours

18.02.2026 18:19 👍 1 🔁 0 💬 0 📌 0

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization Nature Reviews Clinical Oncology, Published online: 18 February 2026; doi:10.1038/s41571-026-01123-4Adjuvant therapy with anti-PD-L1 antibodies and other immune-checkpoint inhibitors (ICIs) is an established standard of care for many patients with surgically resected solid tumours. Nonetheless, the activity of ICIs and ICI-containing combinations in the metastatic setting as well as the emergence of effective neoadjuvant and perioperative approaches involving these agents is challenging the use of adjuvant therapy. In this Review, the authors consider the role of adjuvant therapy in patients with resected solid tumours, including the potential for personalization based on recurrence risk and/or the presence of specific biomarkers.

18.02.2026 18:19 👍 1 🔁 0 💬 0 📌 0

CDK4/6 inhibition provides additional efficacy in HER2+, HR+ breast cancer Nature Reviews Clinical Oncology, Published online: 17 February 2026; doi:10.1038/s41571-026-01133-2CDK4/6 inhibition provides additional efficacy in HER2+, HR+ breast cancer

17.02.2026 18:58 👍 1 🔁 0 💬 0 📌 0

Cancer statistics, 2026: divergent trends and the implementation gap Nature Reviews Clinical Oncology, Published online: 16 February 2026; doi:10.1038/s41571-026-01132-3New epidemiological data from the American Cancer Society indicate a continued decline in overall cancer mortality in the USA but also reveal alarming countertrends. Rising advanced-stage presentation of prostate cancer, an accelerating incidence of early-onset colorectal cancer, and widening disparities in uterine and lung cancer outcomes underscore that the next frontier in oncology is equitable delivery, not just biological discovery.

16.02.2026 12:59 👍 0 🔁 0 💬 0 📌 0

Sacituzumab govitecan plus pembrolizumab improves outcomes Nature Reviews Clinical Oncology, Published online: 11 February 2026; doi:10.1038/s41571-026-01129-ySacituzumab govitecan plus pembrolizumab improves outcomes

12.02.2026 09:03 👍 0 🔁 0 💬 0 📌 0

Engineering platelets as cancer therapeutics Nature Reviews Clinical Oncology, Published online: 06 February 2026; doi:10.1038/s41571-026-01122-5Platelets can promote cancer progression through either direct and indirect mechanisms, and they can also suppress tumour progression in certain contexts. The authors of this Review discuss how insights on these properties have been leveraged to develop cancer therapies in which platelets are engineered to act as targeted delivery vehicles or as active effector cells, outlining opportunities and challenges for clinical translation.

06.02.2026 21:45 👍 1 🔁 1 💬 0 📌 1

Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma Nature Reviews Clinical Oncology, Published online: 05 February 2026; doi:10.1038/s41571-026-01125-2Novel immunotherapy combinations are now available for second or later-line therapy for follicular lymphoma. The addition of tafasitamab, an anti-CD19 antibody, or epcoritamab, a CD20 × CD3 bispecific antibody, to lenalidomide–rituximab (R2) has demonstrated promising efficacy. Herein, I compare recent phase III trials testing each combination and discuss their practical implications.

05.02.2026 21:04 👍 0 🔁 0 💬 0 📌 0

Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer Nature Reviews Clinical Oncology, Published online: 03 February 2026; doi:10.1038/s41571-026-01120-7Premenopausal women aged

04.02.2026 06:46 👍 1 🔁 1 💬 0 📌 0

Anbenitamab is a new second-line option in G/GEJ adenocarcinoma Nature Reviews Clinical Oncology, Published online: 28 January 2026; doi:10.1038/s41571-026-01124-3Anbenitamab is a new second-line option in G/GEJ adenocarcinoma

28.01.2026 21:02 👍 1 🔁 0 💬 0 📌 0

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer Nature Reviews Clinical Oncology, Published online: 23 January 2026; doi:10.1038/s41571-025-01115-wThis Review outlines the fundamental role of chimeric antigen receptor (CAR) T cell therapy for children, adolescents and young adults (CAYAs) with relapsed and/or refractory B cell acute lymphoblastic leukaemia, emphasizing the crucial need to further exploit CAR T cells and other immunotherapies to improve survival with broadened access across disease states. Opportunities and challenges for expanding CAR T cell therapy to other haematological and non-haematological malignancies in CAYAs are also discussed.

23.01.2026 10:20 👍 1 🔁 0 💬 0 📌 0

Diagnosis, risk stratification and management of smouldering multiple myeloma Nature Reviews Clinical Oncology, Published online: 22 January 2026; doi:10.1038/s41571-026-01119-0Increased understanding of the biology of smouldering multiple myeloma (SMM) is being leveraged to improve the management of this clinically heterogeneous precursor of MM. This Review describes the current diagnostic work-up, risk stratification and management of SMM, highlighting early intervention approaches for high-risk SMM that might provide the best opportunity to convert MM into a curative disease and discussing persistent challenges in this field.

23.01.2026 00:41 👍 2 🔁 1 💬 0 📌 0

Author Correction: Advances in the management of localized bladder cancers Nature Reviews Clinical Oncology, Published online: 19 January 2026; doi:10.1038/s41571-026-01121-6Author Correction: Advances in the management of localized bladder cancers

20.01.2026 09:01 👍 0 🔁 0 💬 0 📌 0

MicroRNAs in oncology: a translational perspective in the era of AI Nature Reviews Clinical Oncology, Published online: 15 January 2026; doi:10.1038/s41571-025-01114-xDespite well-established roles of microRNAs (miRNAs) as tumour suppressors or oncogenes, miRNA-based diagnostics, prognostic tools and treatments have yet to be incorporated into routine oncology practice. In this Review, the authors discuss innovative approaches to address challenges in the clinical translation of miRNA-based diagnostics and treatments by integrating fundamental miRNA biology, multiomics and artificial intelligence-driven analyses.

16.01.2026 09:00 👍 5 🔁 2 💬 0 📌 0

A guide to cancer screening Nature Reviews Clinical Oncology, Published online: 07 January 2026; doi:10.1038/s41571-025-01112-zCancer screening aims to identify either pre-malignant conditions or earlier-stage disease in non-symptomatic individuals. The authors of this Review recapitulate the general principles of cancer screening, discussing the current screening practices for several cancer types as well as advances in cancer detection that might hold promise for screening an increasing number of cancers in the future.

07.01.2026 20:01 👍 3 🔁 1 💬 0 📌 0

Discovery of predictive biomarkers for cancer therapy through computational approaches Nature Reviews Clinical Oncology, Published online: 06 January 2026; doi:10.1038/s41571-025-01109-8Treatment selection based on the presence of one or more specific biomarkers has the potential to optimize treatment outcomes; nonetheless, most patients lack a specific biomarker that is predictive of benefit from one or more targeted treatment approaches. In this Review, the authors describe the potential of computational analysis approaches to enable the discovery of more complex predictive biomarkers based on comprehensive analysis of large clinical and preclinical datasets and thus address this unmet need.

06.01.2026 15:24 👍 2 🔁 1 💬 0 📌 0

Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL Nature Reviews Clinical Oncology, Published online: 06 January 2026; doi:10.1038/s41571-025-01118-7Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL

06.01.2026 13:33 👍 0 🔁 0 💬 0 📌 0

Advances in the management of localized bladder cancers Nature Reviews Clinical Oncology, Published online: 05 January 2026; doi:10.1038/s41571-025-01104-zThe management of localized bladder cancers is rapidly evolving. In this Review, the authors discuss diagnostic innovations, refinements in surgical approaches and novel intravesical or systemic treatments such as immunotherapies and antibody–drug conjugates, as well as future directions including bladder-sparing approaches for muscle-invasive disease and novel biomarkers for personalized treatment and follow-up.

05.01.2026 21:29 👍 2 🔁 0 💬 0 📌 0

The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology Nature Reviews Clinical Oncology, Published online: 05 January 2026; doi:10.1038/s41571-025-01110-1RNA sequencing (RNA-seq) is increasingly being integrated into molecular tumour profiling but remains underutilized for clinical decision-making. This Perspective presents a framework for assessing the therapeutic, diagnostic and prognostic actionability of RNA-seq findings as well as an ‘actionable transcriptome’ list to help guide the application of RNA-seq findings in oncology practice.

05.01.2026 21:29 👍 5 🔁 2 💬 0 📌 0

MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma Nature Reviews Clinical Oncology, Published online: 02 January 2026; doi:10.1038/s41571-025-01116-9MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma

02.01.2026 20:57 👍 2 🔁 0 💬 0 📌 0

From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer Nature Reviews Clinical Oncology, Published online: 15 December 2025; doi:10.1038/s41571-025-01113-yDespite radical cystectomy, residual urothelial cancer cells can persist undetected in patients with muscle-invasive bladder cancer, silently seeding future relapse. New data from the phase III IMvigor011 trial demonstrate that circulating tumour DNA (ctDNA) can be used to effectively stratify patients by recurrence risk, enabling adjuvant atezolizumab to be delivered selectively to those who are likely to benefit. This precision ctDNA-guided strategy might fundamentally reshape postoperative management through alignment of treatment intensity with molecular risk.

15.12.2025 20:55 👍 1 🔁 0 💬 0 📌 0

The global epidemiology of acute myeloid leukaemia Nature Reviews Clinical Oncology, Published online: 05 December 2025; doi:10.1038/s41571-025-01099-7Despite the availability of various novel therapies, the global incidence of acute myeloid leukaemia (AML) has continued to increase. Owing to a combination of population ageing and more effective diagnosis, AML remains much more common in economically developed countries. Conversely, AML is less common in the economically developing world, albeit often with worse outcomes owing to a lack of access to effective therapies. In this Review, the authors describe these global trends as well as their underlying reasons, including the changing landscape of risk factors, demographic disparities and differing treatment outcomes.

05.12.2025 21:24 👍 1 🔁 1 💬 0 📌 0

When ctDNA says ‘maybe’: improving the dynamics of MRD trials Nature Reviews Clinical Oncology, Published online: 01 December 2025; doi:10.1038/s41571-025-01111-0Circulating tumour DNA (ctDNA) has emerged as a promising biomarker enabling the detection of minimal residual disease (MRD) in patients with locally advanced colon cancer. The phase II/III DYNAMIC-III trial, with results recently reported, is a landmark effort to evaluate ctDNA-guided adjuvant treatment in this setting. Here, I discuss how, despite not yet changing clinical practice, these results provide essential insights to guide the next generation of ctDNA-driven trials.

01.12.2025 20:54 👍 2 🔁 1 💬 0 📌 0

The development of CAR T cells for patients with CNS malignancies Nature Reviews Clinical Oncology, Published online: 01 December 2025; doi:10.1038/s41571-025-01102-1Despite advances in the treatment of many advanced-stage solid tumours, the outcomes of patients with central nervous system tumours have not improved substantially for several decades, largely owing to a lack of novel therapies. In this Review, the authors describe the clinical experience with chimeric antigen receptor T cells both in adults and children with these historically difficult to treat malignancies, including some promising signals of efficacy.

01.12.2025 20:54 👍 2 🔁 1 💬 0 📌 0

Nature Reviews Clinical Oncology

Latest posts by Nature Reviews Clinical Oncology @natrevclinonc.nature.com